Passage Bio Sets November 5 Vote on Remix Reverse Merger; Net Cash Estimate Rises to $10.9M
PASG sits 24% above its 52-week low of $3.29.
Summary
Passage Bio's latest S-4 amendment sets a November 5, 2026 special meeting to vote on the Remix reverse merger and updates the anticipated net cash at closing to $10.9 million, up from the $5.0 million assumption in prior filings.
Key Events · M&A and Partnerships · PASG
-
Special Meeting Set for November 5
Passage Bio stockholders will vote on the Remix reverse merger at a virtual special meeting on November 5, 2026. The record date is September 30, 2026, with 3,217,810 shares outstanding and entitled to vote.
-
Net Cash Estimate Rises to $10.9M
Anticipated Passage Bio Net Cash at Closing is now approximately $10.9 million, up from the $5.0 million assumption used in the exchange ratio formula in earlier filings. Higher net cash increases Passage Bio's valuation and modestly improves existing stockholders' ownership percentage.
-
Ownership Split Unchanged at 6%/65%/29%
Post-merger ownership remains approximately 6% for Passage Bio stockholders, 65% for Remix equityholders, and 29% for Concurrent Financing investors, subject to adjustment based on final net cash.
-
Stock Price Near Nasdaq Minimum
Passage Bio Common Stock closed at $4.12 on October 2, 2026, just above the $4.00 minimum bid price required for the combined company to maintain Nasdaq listing after the proposed 1-for-2 to 1-for-10 reverse stock split.
Analysis · PASG · Life Sciences
This Amendment No. 3 to the S-4 finalizes the mechanics of the reverse merger with Remix Therapeutics. The special meeting is now set for November 5, 2026, with a record date of September 30, 2026. Critically, the anticipated Passage Bio Net Cash at Closing has been revised upward to approximately $10.9 million from the $5.0 million assumption used in earlier filings. Under the merger agreement's exchange ratio formula, a higher net cash balance increases Passage Bio's valuation, which would modestly improve the ownership percentage retained by existing Passage Bio stockholders — though they are still expected to own only about 6% of the combined company. The filing also confirms the stock closed at $4.12 on October 2, 2026, just above the $4.00 minimum bid price required for Nasdaq listing after the proposed reverse stock split.
How filings like this one have moved
In the 30 days to Oct 10, 2026, 36.1% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PASG was trading at $4.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.2M. The 52-week trading range was $3.29 to $20.00. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.